

Patent
100848.213102US4

ribavirin to the patient under a protocol intended to promote the Type 1 response and suppress the Type 2 response, and adding interferon alpha to the lymphocytes.

- 3 ~~6~~. A method of inhibiting a virus by growing a virus in an environment having lymphocytes which produce Type 1 and Type 2 cytokine responses, and adding ribavirin to the environment in a concentration for the purpose of increasing the Type 1 response and suppressing the Type 2 response, wherein the virus comprises Hepatitis C.
- 4 ~~7~~. The method of claim ~~6~~³ wherein the environment comprises a liver.
- 5 ~~8~~. The method of claim ~~6~~³ wherein the environment comprises hepatocytes.
- 6 ~~9~~. The method of claim ~~6~~³ wherein the environment comprises a liver.
- 7 ~~10~~. The method of claim ~~6~~³ wherein the environment comprises hepatocytes.

REMARKS

The Final Office Action stated that claims 2, 4, and 6-10 are allowable.

Dependent claim 2 was amended to include the limitations of its parent claim 1 and claim 4 was amended to include the limitations of its parent claim 3.

The examiner indicated that revised claims 1, 3, and 5 were still invalid under statutory double patenting as being drawn to the same invention as previously issued claims. Claims 1, 3, and 5 are canceled herein.

Claims 11-16 were deemed withdrawn and are now cancelled in favor of a divisional filing.